- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Suven Life Sciences Limited — Board Meeting, 06-08-2026: Outcome of Board Meeting
06-08-2026 | 12:47 pm
06-08-2026 | 12:47 pm
Suven Life Sciences' Board approved Q1 financial results. Consolidated net loss was ₹127.61 Cr, with total income at ₹11.09 Cr. Clinical trials advanced with 95% enrollment for SUVN-502 Phase 3 and SUVN-G3031 Phase 3 initiated. Proceeds from preferential warrants continue to be received.
No comments yet. Be the first to comment!